Download PDF
Thromb Haemost 1970; 23(01): 091-098
DOI: 10.1055/s-0038-1654123
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Inhibition of Platelet Aggregation by Dialysable Fibrinogen Degradation Products (FDP)

Jolanta Stachurska
1   Department of Biochemistry, Institute of Rheumatology, and from the Department of Radiobiology and Health Protection, Institute of Nuclear Research, Warsaw
,
Z Latałło
1   Department of Biochemistry, Institute of Rheumatology, and from the Department of Radiobiology and Health Protection, Institute of Nuclear Research, Warsaw
,
Maria Kopeć
1   Department of Biochemistry, Institute of Rheumatology, and from the Department of Radiobiology and Health Protection, Institute of Nuclear Research, Warsaw
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

    Permissions and Reprints

Summary

During prolonged proteolysis of fibrinogen by plasmin dialysable, low molecular fragments accumulate which inhibit platelet aggregation induced by thrombin, ADP, adrenaline and noradrenaline. These fragments isolated by dialysis were separated on sephadex G-25 column. The active component has probably a molecular weight lower than 5,000 and does not contain aromatic amino acids.

 

  • References

  • 1 Barnhart M. J, Cress D. C, Henry R. L, Riddle J. M. Influence of fibrinogen split products on platelets. Thrombos. Diathes. haemorrh. (Stuttg.) 17: 78 1967;
    PubMedGoogle Scholar
  • 2 Booyse M, Rafelson Jr. M. Studies on human platelets III. A contractile protein model for platelet aggregation. Blood 33: 100 1969;
    PubMedGoogle Scholar
  • 3 Buluk K, Malofiejew M, Czokalo M. Unknown properties of the products of plasmin degradation of fibrinogen and fibrin. Bull. Acad. Pol. Sci Cl VI 14: 193 1966;
    PubMedGoogle Scholar
  • 4 Chambers D. A, Salzman E. W, Neri L. L. Characterization of ecto ATP-ase of human blood platelets. Arch. Biochem 119: 173 1967;
    CrossrefPubMedGoogle Scholar
  • 5 Cronberg S. Effect of fibrinolysis on adhesion and aggregation of human platelets. Thrombos. Diathes. haemorrh. (Stuttg.) 19: 474 1968;
    PubMedGoogle Scholar
  • 6 Hagan J. J, Ablondi F. B, Benso E. C. Purification and biochemical properties of human plasminogen. J. biol. Chem 235: 1005 1960;
    PubMedGoogle Scholar
  • 7 Jerushalmy Z, Zucker M. Some effects of fibrinogen degradation products (FDP) on blood platelets. Thrombos. Diathes. haemorrh. (Stuttg.) 15: 413 1965;
    PubMedGoogle Scholar
  • 8 Kekwick R. A, Mackay M. E, Nance M. H, Record B. R. The purification of human fibrinogen. Biochem. J 60: 671 1965;
    PubMedGoogle Scholar
  • 9 Kline D. L. The purification and cristallization of plasminogen (Profibrinolysin). J. biol. Chem 204: 949 1953;
    PubMedGoogle Scholar
  • 10 Kopeć M, Budzyński A. Z, Latałło Z. S, Lipiński B, Stachurska J, Węgrzynowicz Z, Kowalski E. Interaction of platelet and fibrinogen degradation products in hemostasis. In Kowalski E, and Niewiarowski S. (Eds.) Biochemistry of blood platelets. 147 Academic Press; London/New York PWN: Polish Scientific Publishers, Warszawa 1967
    Google Scholar
  • 11 Kopeć M, Budzyński A. Z, Stachurska J, Węgrzynowicz Z, Kowalski E. Studies on the mechanism of interference of fibrinogen degradation products (FDP) with the platelet function. Role of fibrinogen in the platelet atmosphere. Thrombos. Diathes. haemorrh. (Stuttg.) 25: 476 1966;
    PubMedGoogle Scholar
  • 12 Kowalski E, Budzyński A. Z, Kopeć M, Latałło Z. S, Lipiński B, Węgrzynowicz Z. Studies on the molecular pathology and pathogenesis of bleeding in severe fibrinolytic states in dogs. Thrombos. Diathes. haemorrh. (Stuttg.) 12: 69 1964;
    PubMedGoogle Scholar
  • 13 Kowalski E, Kopeć M, Węgrzynowicz Z. Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thrombos. Diathes. haemorrh. (Stuttg.) 10: 406 1964;
    PubMedGoogle Scholar
  • 14 Larrieu M. J, Inceman S, Marder V. Action des produits de degradation du fibrinogene sur les fonctions plaquettaires. Nouv. Rev. franç. Hémat 7: 691 1967;
    PubMedGoogle Scholar
  • 15 Larrieu M. J, Marder V. J, Inceman S. Effects of fibrinogen degradation products on platelets and coagulation. In Koller F, and Streuli F. (Eds.) Diffuse intravascular clotting. Trans. Int. Comm. on Haemostasis and Thrombosis, 1965. 215 Schattauer; Stuttgart: 1966
    Google Scholar
  • 16 Lüscher E. F. Biochemistry of viscous metamorphosis and retraction. Exp. Biol. Med 3: 112 1968;
    PubMedGoogle Scholar
  • 17 Nachman R. L. A, Marcus J, Softer L. B. Platelet thrombosthenin subcellular location and function. J. clin. Invest 46: 1380 1967;
    CrossrefPubMedGoogle Scholar
  • 18 Osbahr A. J, Gladner J. A, Laki K. Studies on the physiological activity of the peptide released during the fibrinogen-fibrin conversion. Biochim. biophys. Acta (Amst.) 86: 535 1964;
    CrossrefPubMedGoogle Scholar
  • 19 Paliwoda H, Lui J, Wolf R, Christi H. L. Über den Einfluß von Fibrinogenspaltprodukten auf die Entstehung plättchenreicher Abscheidungsthromben. Thrombos. Diathes. haemorrh. (Stuttg.) 19: 540 1968;
    PubMedGoogle Scholar
  • 20 Prentice C. R. H, Turpic A. G. G, Hassanein A. A, McNicol G. P. Changes in platelet behaviour during arvin therapy. Lancet I: 644 1969;
    PubMedGoogle Scholar
  • 21 Salzman E. W, Chambers D. A, Neri L. L. Mechanism of inhibition of ADP induced platelet aggregation by diguanidino compounds. Fed. Proc 25: 554 1966;
    PubMedGoogle Scholar
  • 22 Thomas D. P, Rean V. J, Stuart R. K. Platelet aggregation in patients with Laennec’s cirrhosis of the liver. New Engl. J. Med 276: 1344 1967;
    CrossrefPubMedGoogle Scholar